We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

March 7, 2019

Show me the evidence - Impact of Theranos, et al.

Commentary
Sophie Madden
&

With the preview of HBOs new documentary ‘The Inventor’ at Sundance film festival earlier this month, talk of failed digital health start-up Theranos has reached new heights. It seems the downfall of Elizabeth Holmes and her blood-based diagnostic company has seriously gripped the attention of those in the digital health space, and well beyond. John Carreyrou’s best selling book ‘Bad Blood - Secrets and Lies in a Silicon Valley Startup’, which analyses the rise and monumental fall of Theranos, has been critically acclaimed and is flying off bookshelves around the world.

In this weeks blog, we take a look at how the unprecedented public interest in the Theranos case has impacted the digital health space, sparking questions around digital health valuations, due diligence, and clinical evidence.

Overpromise and Underdeliver

In case you’ve missed it, here's a quick overview of the Theranos story:

Theranos was founded in 2003 by Elizabeth Holmes when she was just 19 years old. Holmes claimed that Theranos had developed a blood-based diagnostic device that only required microscopic blood volumes (significantly lower than any similar products on the market) to run a full range of laboratory tests and committed to delivering results in a day - some tests take way longer in current practice. The tests ranged from basic CBC (complete blood count) to infectious disease to oncology diagnosis - quite a wide range for one small device and one drop of blood to accomplish. Theranos lured in investors, who collectively invested a staggering $700 million. It wasn’t just the investors that were fooled, large pharmaceutical companies GSK and Pfizer also saw huge potential in the solution, as well as Cleveland Clinic and Walgreens, who trialled the Theranos ‘device’. Holmes managed to form a high profile board of directors which included George Shultz and Henry Kissinger. In 2015, John Carreyrou, who was then reporting for the Wall Street Journal, suggested that the Theranos technology had never actually worked as they claimed, and this report triggered investigations from the FDA, CMS and SEC, ultimately leading to the downfall of Theranos and their official closing in 2018. Elizabeth Holmes is currently facing fraud charges.

So, just how did Theranos manage to get into the hands of patients long before anyone realised that the technology didn't actually work? And what can we learn from this?

1.The entrepreneur hero syndrome. Holmes, who was dubbed ‘the next Steve Jobs’, sold her daring vision of what her company could be so well that what it actually was was majorly overlooked. She also managed to get an esteemed board of directors which included former cabinet secretaries and senators, and while these people are highly revered, none of them actually have any experience in the healthcare space, let alone in home-diagnostic technology. Perhaps if they had, red flags would have been raised a lot earlier? Holmes also attempted to pit people and teams against each other in order to speed up the production process, creating an environment that was not conducive to collaboration. For the most part, employees who challenged the veracity of Theranos claims were let go, and potential whistleblowers were threatened with lawsuits.

2. Raising capital ≠ success. The Silicon Valley mantra of ‘Fail fast. Fail hard’ fosters an environment in which huge amounts of capital can be pumped into promising startups with the expectation that failures will happen along the road as these solutions adapt to find their niche in the market. This led to Theranos raising $700M, without ever pausing to reassess where the money was going, why there was such a high cash burn rate, and why they hadn’t demonstrated robust clinical evidence to validate Holmes’ claims of the products capabilities. (See Juicero for another example of why capital should not equate to guaranteed success…)

3.Fear Of Missing Out - Are the likes of Walgreens really to be blamed for wanting in on the action, particularly with the public interest, esteemed board members, and industry hype that Theranos had? As John Carreyrou references, the fear of missing out on the next big opportunity to a competitor is a major driver for those in the healthcare industry, and is seemingly what drove Walgreens to roll out the Theranos device in their stores.

Clinical Validation

Popularity does not validate a solution.

Typically, blood samples undergo a somewhat complicated journey that involves first collecting adequate amounts of blood from a patient, then transporting them to a facility, where they are either mixed with chemicals or put through various pieces of equipment to be examined. It's during this dilution and transfer of liquids that errors occur. Potential complications can arise if the sample's freshness isn't properly maintained during transit or while manually centrifuging samples to separate plasma and red and white blood cells. The risk of an error is compounded by the fact that labs use equipment from different vendors, which aren't always properly/ regularly calibrated. Follow-up tests also tend to make the process even more time-consuming, error-prone and expensive.

A solution that could address many of the pain points above is obviously welcome. The idea that one singular drop of blood could be analysed and used to run the full range of laboratory tests to deliver accurate results was highly ambitious. But it is an idea that deserves layers of proof - in the form of clinical trials, real world/ post marketing data, and compliance with guidelines from regulatory bodies like the CLIA and FDA. Failing to produce this should mean we do not accept such a solution into our practice.



Digital health valuations - too good to be true?

At its peak, Theranos had a valuation of $9B. Their story is a cautionary tale of how hype surrounding digital health solutions and their valuations can rapidly spiral out of control. The potential opportunity for finding and investing in the elusive ‘panacea’ for all that is wrong with our current healthcare system seemingly blinded those in the healthcare space to the many red flags of Theranos.

A review published in January 2019 titled ‘Stealth Research - Lack of peer-reviewed evidence from healthcare unicorns’ highlights how over half of current unicorns and almost 40% of exit unicorns have no highly cited papers. One example from the review highlights how Outcome Health, a healthcare unicorn that raised $500M and was valued at $5B, had no published literature or documented RWE as proof of concept. Should this have served as a predictor to their subsequent failure? (Outcome Health investors sued the company and its founders for fraud after allegations that it had overcharged clients and misled them about their campaigns.) Their product was a monitor that was placed in the physician's office to educate patients on their condition and also act as a marketing device for pharmaceutical products. While this is a low risk intervention, the lack of any sort of third-party validation should have been a red flag. As noted in the review:

"Startups are key purveyors of innovation: Holding them to a minimum standard of evaluation is essential’’

Show me the evidence

With scepticism high, others saw an opportunity to take the interest in the home diagnostic space and use it to their advantage. Recognising the growing interest in blood based diagnostics, and the potential for a solution that actually worked, this industry is booming.

The story of Theranos hasn’t deterred investors from similar solutions either. Athelas, 1Drop Diagnostics, Genalyte, Osler Diagnostics, Orphidia, Sight Diagnostics, and NowDiagnostics, have all developed similar products to Theranos, and collectively have raised over $225M.

Osler Diagnostics was developed under Oxford Sciences Innovation, and claim to be working on a handheld diagnostic device that enables the detection of biomarkers present in cancers, cardiovascular and neurological diseases from a drop of blood. Interestingly, they just closed a $35M fundraising round from a solo investor, and yet their website doesn’t contain any information and they have no published research. It is understandable that people are not jumping to share their ideas and IPs in such a competitive market, but making judgements in the absence on information is a risky business.

Athelas, who have raised $3M, have developed a portable diagnostic device leveraging deep learning and machine vision to rapidly measure white blood cell count to identify leukemia, infections, and  inflammation. Its 60-second at-home blood test is reportedly capable of testing for diseases such as the flu, bacterial infections and even cancer. Currently, the device is being used for cancer patients to monitor white blood cell counts for chemotherapy. Contrary to Theranos, Athelas tries to differentiate itself with a data-oriented approach and it’s working closely with regulatory agencies in a number of capacities including the design of its trials.

Conclusion

The story of Theranos should lead to intensified visibility and transparency into digital health solutions, however it does not appear to have had caused a tidal shift in the digital health space.

For investors and potential partners, this story highlights how important due diligence is, and how the competition to get in on the action can often lead to important factors being overlooked.

HealthXL advisor and friend Lisa Suennen, who has extensive experience in the VC and digital health space, aptly said that:

‘’Digital health success cannot be defined by investment statistics. We must see evidence of efficacy, both clinical and financial, in order to declare a company a possible success.  And in the end, these companies will have to produce material returns for their investors - given the amount of money that has poured into the sector, we have yet to see more than handful of superior financial outcomes.’’

For those who tackle head on the areas Theranos fell down, there is a hopeful future. DTC blood testing companies who want to play in this space will need to be transparent with their evidence of efficacy, work closely with regulators to address unprecedented market pathways, and respect pre-existing regulations.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.